ICON recently participated in the PHUSE US Connect Conference, held February 25-28 in Bethesda, Maryland.
PHUSE, the organiser, is a global non-profit organisation serving the life sciences industry. Run by volunteers with industry expertise, PHUSE fosters collaboration across data management, biostatistics, statistical programming, data science, and eClinical IT. Importantly, PHUSE also advocates for the industry, representing its voice to regulatory agencies like the FDA, EMA, and CDISC. The conference brought together 677 attendees from 173 companies across 18 countries.
The conference had an opening keynote followed by 6 concurrent sessions grouped into 17 distinct topics and 9 primary conference themes:
Topics | Themes |
Analytics and Statistics | AI for Clinical Data Scientists |
Analytical Risk Based Monitoring | Digital Data Flow |
Data Handling and Engineering | End-to-End with R Packages from SDTM to TFL |
Data Standards and Governance | Global Leadership and Team Excellence: Navigating Borders, Minds and Success |
Data Visualisation | Insights into Risk-Based Monitoring Practices |
Emerging Trends | Navigating Open Source in the Clinical Data Space |
Leadership | Oncology Programming Excellence: Strategies from RECEIST to ISE |
Open-Source Technologies | Real-World Insights: Mapping, Scaling and Integration |
People Leadership and Management | Tools for Data Exploration and Reporting Advancements |
Poster Presentations | |
Professional Development | |
Real-World Evidence | |
Scripts, Macros and Automation | |
Software Demonstrations | |
Standards Implementation | |
Submissions and Agencies | |
Therapeutic Area Specific Topics |
In addition to the above topics, there was a dedicated stream for the PHUSE/FDA Innovation Challenge. Participants were invited to work on prototypes and to present their proof-of-concepts or solutions.
This year, the theme was "Application of AI/ML Methodologies", with presentations falling within the following two pillars:
- Risk Based Monitoring
Throughout all stages of the clinical investigation, managing both risks to participants (e.g. safety problems) and to data integrity (e.g. incomplete and/or inaccurate data).
- Clinical Trial Developments
Development across clinical trial activities, such as data collection, data comparison and/or data analysis practices.
The FDA, recognising the potential of AI/ML to revolutionise new drug development, sought collaboration with the industry to gain insights into the latest applications of this rapidly advancing technology. A competition was held, with winning ideas chosen for further development by PHUSE working groups in partnership with the FDA.
ICON presented a poster and a paper on the following topics of special interest:
Poster presentation by Elena Valkanova and Bulat Fatykhov: "Comparison of Standard Log-Rank Test with Selected Alternatives"
In oncology studies with time-to-event outcomes, the hazard and survival functions are two ways of specifying a survival distribution. Using the constant hazard assumption for the exponential distribution could provide misleading conclusions. The clinical trial designs with two groups based on proportional hazards (PH) assumption are likely to be underpowered to detect treatment effects. When the PH assumption is violated, the likelihood estimator depends on underlying censoring time distribution.
Selected alternative methods for survival analysis when the assumption for the proportional hazards is questionable were compared and assessed the impact of sample size. Three selected methods – log-rank (LR), max-combo (MC) and restricted mean survival time (RMST) – applied to both simulation data and real clinical trial data, were presented with graphical presentations using R.
Shabeeb Kannattikuni presented a paper co-authored by Karthika Bhavadas: "A SAS Tool for Generating Adverse Event Summaries in XML Format Using ADaM Datasets, ADSL and ADAE for ClinicalTrial.Gov and EudraCT Submissions"
Clinical trial submissions to regulatory authorities require accurate and standardised adverse event summaries in XML format. Shabeeb presented a novel SAS® tool designed to streamline the process of generating comprehensive AE summaries using the ADaM while producing output in XML format adhering to the required schema and data standards for submission to ClinicalTrials.gov and the EudraCT.
To assess the performance and accuracy of the SAS® tool, a validation study was conducted using multiple real-world clinical trial data. The results demonstrate that the tool significantly expedites the AE summary generation process, reducing manual effort and minimising the risk of error in XML creation. The generated XML files conform to the industry-standard data structures and are readily suitable for direct submission to ClinicalTrials.gov and EudraCT platforms, promoting data integrity and expediting regulatory review.
Conclusion
The PHUSE conference offered a wealth of opportunities for attendees to connect and share knowledge on a range of technical subjects. A significant emphasis was placed on practical applications of Generative AI and various programming techniques using popular open-source languages such as R and Python.
The diverse audience, which included representatives from CROs, pharmaceutical companies, biotech firms, and technology vendors, fostered a valuable exchange of experiences and current implementations. This environment facilitated the creation of new relationships that hold promise for future collaborations in both business and technology advancements.
Kent Letourneau
In this section
-
Digital Disruption
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Digital Disruption whitepaper
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel